AUSTIN, Texas, Oct. 20, 2011 /PRNewswire/ --Genprex, Inc. announced today that it will be presenting at the upcoming BIO Investor Forum, to be held in San Francisco. Greg Heinlein, Chief Operating and Financial Officer, is scheduled to present at the 10th annual BIO Investor Forum, on October 25 starting at 11 a.m. PDT in The Palace Hotel. A copy of the presentation slides will be made available on the company's website under the News & Media section on the day of the presentation.
About Genprex
Genprex, Inc. is a privately-held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of TexasMD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.
About Oncoprex
Oncoprex, our first product candidate, is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.
SOURCE Genprex, Inc.
